The proportion of T cells was between 18%‐25%, which is essentially consistent with the abundance of T cell infiltration in surgically resected tissues from patients.[16] Next, we found that applying JMS‐17‐2 treatment could significantly increase the proliferative capacity of CD8+ T cells, suggesting a stronger tumor reactivity (Figure S4J, Supporting Information). This evidence concerns the gene CD8A and neoplasm.